Katsunori Sakamoto, et al. “Treatment Interval as a Prognostic Marker in Patients Undergoing Repeated Curative‐Intent Local Treatment for Recurrent Hepatocellular Carcinoma.” Hepatology Research, 2026. doi:10.1111/hepr.70235.
@article{Sakamoto2026,
title = {Treatment Interval as a Prognostic Marker in Patients Undergoing Repeated Curative‐Intent Local Treatment for Recurrent Hepatocellular Carcinoma},
author = {Sakamoto, Katsunori and Yoh, Tomoaki and Nomura, Satoshi and Kadono, Kentaro and Kojima, Hidenobu and Sato, Asahi and Kageyama, Shoichi and Hirao, Hirofumi and Nishio, Takahiro and Okumura, Shinya and Ueda, Daisuke and Okuno, Masayuki and Nishino, Hiroto and Yamane, Kei and Hirata, Masaaki and Ogiso, Satoshi and Okamoto, Tatsuya and Nagai, Kazuyuki and Uchida, Yoichiro and Ito, Takashi and Ishii, Takamichi and Hatano, Etsuro},
journal = {Hepatology Research},
year = {2026},
doi = {10.1111/hepr.70235},
url = {https://onlinelibrary.wiley.com/doi/10.1111/hepr.70235?af=R}
}
ABSTRACT Background Aspergillus fumigatus can cause life‐threatening infections, primarily treated with azole antifungals. Azole‐resistant A. fumigatus (ARAF) is a major clinical concern. Environmental resistance development is an...
ABSTRACT Background The lipid‐dependent yeast genus Malassezia is composed of skin commensals that can become pathogenic. This genus can cause bloodstream infection in low‐weight preterm neonates and immunocompromised adults. However,...